中红医疗
(300981)
| 流通市值：14.10亿 | | | 总市值：44.77亿 |
| 流通股本：1.23亿 | | | 总股本：3.90亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 544,935,917.11 | 2,105,249,607.06 | 1,581,745,922.68 | 998,882,650.75 |
| 营业收入 | 544,935,917.11 | 2,105,249,607.06 | 1,581,745,922.68 | 998,882,650.75 |
| 二、营业总成本 | 536,883,556.59 | 2,086,359,153.26 | 1,537,141,757.31 | 968,977,169 |
| 营业成本 | 482,745,672.58 | 1,850,526,393.88 | 1,383,388,167.53 | 887,877,135.35 |
| 税金及附加 | 4,854,136.48 | 21,266,458.16 | 15,219,471.33 | 10,758,116.74 |
| 销售费用 | 30,334,217.16 | 105,940,801.66 | 81,550,542.21 | 53,188,088.48 |
| 管理费用 | 24,193,496.93 | 114,610,146.63 | 77,104,491.39 | 41,919,522.7 |
| 研发费用 | 9,612,140.03 | 31,606,065.08 | 24,136,595.38 | 14,102,638.36 |
| 财务费用 | -14,856,106.59 | -37,590,712.15 | -44,257,510.53 | -38,868,332.63 |
| 其中:利息费用 | 4,539,454.71 | 15,353,607.99 | 11,336,004.31 | 6,504,655.44 |
| 其中:利息收入 | 16,827,549.92 | 44,706,303.58 | 31,190,153.73 | 18,921,458.55 |
| 加:公允价值变动收益 | 11,323,317.77 | 60,190,058.51 | 41,980,258.9 | 27,349,315.13 |
| 加:投资收益 | 6,722,350.31 | 22,758,804.19 | 12,420,276.75 | 10,366,953.31 |
| 资产处置收益 | -8,127.18 | 871,650.12 | -83,971.26 | -108,583.62 |
| 资产减值损失(新) | -29,368,758.08 | -253,884,666.39 | -113,383,790.16 | -86,927,479.2 |
| 信用减值损失(新) | 1,062,486.69 | -8,093,214.77 | 6,564,473.85 | 2,642,925.28 |
| 其他收益 | 8,923,506.19 | 22,393,845.94 | 17,635,598.83 | 13,581,121.09 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 6,707,136.22 | -136,873,068.6 | 9,737,012.28 | -3,190,266.26 |
| 加:营业外收入 | 72,293.72 | 1,122,502.88 | 41,820.11 | 39,813.57 |
| 减:营业外支出 | 917,745.99 | 1,919,512.09 | 1,221,881.3 | 531,447.1 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 5,861,683.95 | -137,670,077.81 | 8,556,951.09 | -3,681,899.79 |
| 减:所得税费用 | 4,482,330.38 | -10,003,055.31 | -1,091,165.99 | -3,079,436.1 |
| 六、净利润 | 1,379,353.57 | -127,667,022.5 | 9,648,117.08 | -602,463.69 |
| 持续经营净利润 | 1,379,353.57 | -127,667,022.5 | 9,648,117.08 | -602,463.69 |
| 归属于母公司股东的净利润 | 1,287,194.84 | -130,870,579.41 | 9,197,195.77 | -4,942,596.19 |
| 少数股东损益 | 92,158.73 | 3,203,556.91 | 450,921.31 | 4,340,132.5 |
| (一)基本每股收益 | 0 | -0.34 | 0.02 | -0.01 |
| (二)稀释每股收益 | 0 | -0.34 | 0.02 | -0.01 |
| 八、其他综合收益 | 1,443,138.44 | -1,459,233.74 | 2,791,206.18 | 2,117,454.54 |
| 归属于母公司股东的其他综合收益 | 1,443,138.44 | -1,459,233.74 | 2,791,206.18 | 2,117,454.54 |
| 九、综合收益总额 | 2,822,492.01 | -129,126,256.24 | 12,439,323.26 | 1,514,990.85 |
| 归属于母公司股东的综合收益总额 | 2,730,333.28 | -132,329,813.15 | 11,988,401.95 | -2,825,141.65 |
| 归属于少数股东的综合收益总额 | 92,158.73 | 3,203,556.91 | 450,921.31 | 4,340,132.5 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-25 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |